$MAIA
MAIA Biotechnology, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024125474 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.521M
YoY Change -35.43%
% of Gross Profit
Research & Development $2.667M
YoY Change 2.6%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.188M
YoY Change -15.48%
Operating Profit -$4.188M
YoY Change -15.48%
Interest Expense $85.00
YoY Change 8400.0%
% of Operating Profit
Other Income/Expense, Net $1.346M
YoY Change 1656.89%
Pretax Income -$2.736M
YoY Change -43.89%
Income Tax
% Of Pretax Income
Net Earnings -$2.736M
YoY Change -43.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$0.11
COMMON SHARES
Basic Shares Outstanding 25.33M 23.91M
Diluted Shares Outstanding 23.89M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.691M
YoY Change 42.36%
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets $495.7K
YoY Change 19.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.240M
YoY Change 39.3%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.800K
YoY Change 0.0%
Total Long-Term Assets $2.800K
YoY Change -99.24%
TOTAL ASSETS
Total Short-Term Assets $9.240M
Total Long-Term Assets $2.800K
Total Assets $9.243M
YoY Change 32.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.152M
YoY Change -6.04%
Accrued Expenses $2.457M
YoY Change -15.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.609M
YoY Change -13.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $4.015M
YoY Change 3782.94%
Total Long-Term Liabilities $4.015M
YoY Change 3782.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.609M
Total Long-Term Liabilities $4.015M
Total Liabilities $7.624M
YoY Change 79.25%
SHAREHOLDERS EQUITY
Retained Earnings -$83.66M
YoY Change 44.94%
Common Stock $2.397K
YoY Change 74.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.619M
YoY Change
Total Liabilities & Shareholders Equity $9.243M
YoY Change 32.02%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.736M
YoY Change -43.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.525M
YoY Change 11.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 626.8K
YoY Change 397.71%
NET CHANGE
Cash From Operating Activities -3.525M
Cash From Investing Activities
Cash From Financing Activities 626.8K
Net Change In Cash -2.898M
YoY Change -4.4%
FREE CASH FLOW
Cash From Operating Activities -$3.525M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
2.37
maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P4Y7M13D
maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
0.10
maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
1.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7750152
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.53
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M14D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2437516
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.43
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
118610
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
679531
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.62
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9389527
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7041164
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7232697
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M9D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6336419
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001878313
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41455
dei Entity Registrant Name
EntityRegistrantName
MAIA BIOTECHNOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1495913
dei Entity Address Address Line1
EntityAddressAddressLine1
444 West Lake Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1700
dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60606
dei City Area Code
CityAreaCode
312
dei Local Phone Number
LocalPhoneNumber
416-8592
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
MAIA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25332069
CY2024Q3 us-gaap Cash
Cash
8690784
CY2023Q4 us-gaap Cash
Cash
7150695
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
495650
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
268677
CY2024Q3 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
53608
CY2023Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
144680
CY2024Q3 us-gaap Assets Current
AssetsCurrent
9240042
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7564052
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2024Q3 us-gaap Assets
Assets
9242842
CY2023Q4 us-gaap Assets
Assets
7566852
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1152055
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1638546
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2456844
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298607
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3608899
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4937153
CY2024Q3 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
4015352
CY2023Q4 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
2152188
CY2024Q3 us-gaap Liabilities
Liabilities
7624251
CY2023Q4 us-gaap Liabilities
Liabilities
7089341
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23966814
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23966814
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16986254
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16986254
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2397
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1699
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85290791
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64472249
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83662895
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63980177
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11702
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16260
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1618591
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
477511
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9242842
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7566852
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2667170
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2599578
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7040145
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7394884
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1521298
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2356065
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4912461
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6409655
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4188468
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4955643
us-gaap Operating Expenses
OperatingExpenses
11952606
us-gaap Operating Expenses
OperatingExpenses
13804539
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4188468
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4955643
us-gaap Operating Income Loss
OperatingIncomeLoss
-11952606
us-gaap Operating Income Loss
OperatingIncomeLoss
-13804539
CY2024Q3 us-gaap Interest Expense
InterestExpense
85
CY2023Q3 us-gaap Interest Expense
InterestExpense
1
us-gaap Interest Expense
InterestExpense
85
us-gaap Interest Expense
InterestExpense
6863
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
106082
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3260
us-gaap Investment Income Interest
InvestmentIncomeInterest
238583
us-gaap Investment Income Interest
InvestmentIncomeInterest
3768
CY2024Q3 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
15198
CY2023Q3 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
58448
maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
51847
maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
149457
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1331286
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18193
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8007505
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-141934
maia Gain Loss Fair Value Of Warrants Over Proceeds
GainLossFairValueOfWarrantsOverProceeds
-12952
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1452481
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
79900
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-7730112
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
288296
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2735987
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4875743
us-gaap Profit Loss
ProfitLoss
-19682718
us-gaap Profit Loss
ProfitLoss
-13516243
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2735987
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4875743
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19682718
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13516243
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23894980
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23894980
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13675802
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13675802
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21249725
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21249725
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12521264
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12521264
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2735987
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4875743
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19682718
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13516243
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
10476
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-17858
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4558
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-43766
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2725511
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4893601
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19678160
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13560009
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
477511
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
11500
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
349965
CY2024Q1 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-13786
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-8067455
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5764928
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185646
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
413948
CY2024Q2 maia Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3191675
CY2024Q2 maia Reclassification Of Liability Classified Warrants To Equity
ReclassificationOfLiabilityClassifiedWarrantsToEquity
6870296
CY2024Q2 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
7868
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-8879276
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3161895
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
100000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30192
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
455388
CY2024Q3 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
10476
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2735987
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1618591
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
164070
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
537522
CY2023Q1 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-9301
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4116876
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5083208
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
324260
CY2023Q2 maia Stock Issued During Period Value Warrants To Underwiter
StockIssuedDuringPeriodValueWarrantsToUnderwiter
241109
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
618932
CY2023Q2 maia Issuance Of Stock Options To Satisfy Accrued Bonus
IssuanceOfStockOptionsToSatisfyAccruedBonus
974224
CY2023Q2 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-634
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-4523624
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6874334
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1433
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
194630
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
570916
CY2023Q3 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-17858
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4875743
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2747712
us-gaap Profit Loss
ProfitLoss
-19682718
us-gaap Profit Loss
ProfitLoss
-13516243
us-gaap Share Based Compensation
ShareBasedCompensation
1219301
us-gaap Share Based Compensation
ShareBasedCompensation
1727369
maia Consulting Expense For Restricted Shares Issued
ConsultingExpenseForRestrictedSharesIssued
111500
maia Consulting Expense For Restricted Shares Issued
ConsultingExpenseForRestrictedSharesIssued
682962
maia Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
8007505
maia Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-141934
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
455388
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
570916
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1219301
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1727369
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
maia Gain Loss Fair Value Of Warrants Over Proceeds
GainLossFairValueOfWarrantsOverProceeds
-12952
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
227368
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-134145
maia Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-92551
maia Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-174613
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-488135
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
64016
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-841874
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1796502
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11796286
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9078570
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
153937
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
215838
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1432
maia Proceeds From Sale Of Common Stock In Follow On Offering
ProceedsFromSaleOfCommonStockInFollowOnOffering
5749875
maia Proceeds From At The Market Offering
ProceedsFromAtTheMarketOffering
8522666
maia Payment Of Offering Transactions Costs
PaymentOfOfferingTransactionsCosts
661043
maia Payment Of Offering Transactions Costs
PaymentOfOfferingTransactionsCosts
1351907
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13331146
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4245463
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5229
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-13233
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1540089
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4846340
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7150695
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10950927
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8690784
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6104587
maia Options Issued For Accrued Bonus
OptionsIssuedForAccruedBonus
974224
maia Warrants Issued To Underwriters In Connection With The Follow On Offering
WarrantsIssuedToUnderwritersInConnectionWithTheFollowOnOffering
241109
maia Warrants Issued In Connection With Private Placement Offering1
WarrantsIssuedInConnectionWithPrivatePlacementOffering1
2049600
maia Warrants Issued In Connection With Private Placement Offering2
WarrantsIssuedInConnectionWithPrivatePlacementOffering2
1190111
maia Warrants Issued In Connection With Private Placement Offering3
WarrantsIssuedInConnectionWithPrivatePlacementOffering3
677919
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-03
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83662895
CY2024Q3 us-gaap Cash
Cash
8690784
CY2024Q3 maia Working Capital
WorkingCapital
5631143
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of the Company’s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the “Common Stock”), stock options and warrants, the embedded features in convertible notes, and accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
702928
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
786999
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
64874
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77942
CY2024Q3 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1160265
CY2023Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
998838
CY2024Q3 maia Accrued Severance Current
AccruedSeveranceCurrent
214899
CY2023Q4 maia Accrued Severance Current
AccruedSeveranceCurrent
824435
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
313878
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
610393
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2456844
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298607
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.25
CY2022Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-01-23
CY2022Q3 maia Class Of Warrant Or Right Date From Which Warrants Or Rights Expire
ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
2027-07-27
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3650278
CY2023Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
2.82
CY2023 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P5Y
maia Class Of Warrants Issued
ClassOfWarrantsIssued
2949169
maia Class Of Warrants Weighted Average Exercise Price Issued
ClassOfWarrantsWeightedAverageExercisePriceIssued
1.65
maia Class Of Warrants Exercised
ClassOfWarrantsExercised
1157201
maia Class Of Warrants Weighted Average Exercise Price Exercised
ClassOfWarrantsWeightedAverageExercisePriceExercised
-1.98
maia Class Of Warrants Expired
ClassOfWarrantsExpired
0
maia Class Of Warrants Weighted Average Exercise Price Expired
ClassOfWarrantsWeightedAverageExercisePriceExpired
0
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5442246
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 maia Rule10 B51 Arrmodifiedflag
Rule10B51Arrmodifiedflag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 maia Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-125474-index-headers.html Edgar Link pending
0000950170-24-125474-index.html Edgar Link pending
0000950170-24-125474.txt Edgar Link pending
0000950170-24-125474-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
maia-20240930.htm Edgar Link pending
maia-20240930.xsd Edgar Link pending
maia-ex31_1.htm Edgar Link pending
maia-ex31_2.htm Edgar Link pending
maia-ex32_1.htm Edgar Link pending
maia-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
maia-20240930_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable